Photo from wikipedia
In Singapore, patients with psoriatic arthritis (PsA) constitute a significant disease burden. There is good evidence for the efficacy of anti‐tumor necrosis factor (anti‐TNF) in PsA; however cost remains a… Click to show full abstract
In Singapore, patients with psoriatic arthritis (PsA) constitute a significant disease burden. There is good evidence for the efficacy of anti‐tumor necrosis factor (anti‐TNF) in PsA; however cost remains a limiting factor. Non‐biologic disease modifying anti‐rheumatic drugs (nbDMARDs) hence remain the first‐line treatment option in PsA in spite of limited evidence. The Singapore Chapter of Rheumatologists aims to develop national guidelines for clinical eligibility for government‐assisted funding of biologic disease modifying anti‐ rheumatic drugs (bDMARDs) for PsA patients in Singapore.
Journal Title: International Journal of Rheumatic Diseases
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!